$675 Million is the total value of Sands Capital Ventures, LLC's 16 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PATH | UIPATH INC | $164,402,000 | -18.0% | 3,811,779 | 0.0% | 24.37% | -19.4% | |
| DASH | Sell | DOORDASH INC | $89,557,000 | -31.0% | 601,454 | -4.6% | 13.27% | -32.2% |
| New | NU HOLDINGS LTD. | $85,704,000 | – | 9,136,835 | +100.0% | 12.70% | – | |
| DICE THERAPEUTICS, INC. | $79,700,000 | -22.7% | 3,148,970 | 0.0% | 11.81% | -24.0% | ||
| New | SAMSARA, INC. | $76,242,000 | – | 2,712,256 | +100.0% | 11.30% | – | |
| SNOW | Sell | SNOWFLAKE INC | $72,703,000 | -24.1% | 214,621 | -32.2% | 10.78% | -25.4% |
| KRTX | KARUNA THERAPEUTICS, INC. | $35,094,000 | +7.1% | 267,895 | 0.0% | 5.20% | +5.3% | |
| ABOS | ACUMEN PHARMACEUTICALS, INC | $23,099,000 | -54.5% | 3,417,075 | 0.0% | 3.42% | -55.3% | |
| New | SAMSARA, INC. | $9,164,000 | – | 326,000 | +100.0% | 1.36% | – | |
| TSHA | TAYSHA GENE THERAPIES INC | $8,445,000 | -37.4% | 724,873 | 0.0% | 1.25% | -38.5% | |
| MASS | 908 DEVICES INC | $8,445,000 | -20.4% | 326,427 | 0.0% | 1.25% | -21.8% | |
| CANDEL THERAPEUTICS, INC | $6,348,000 | -27.9% | 811,737 | 0.0% | 0.94% | -29.1% | ||
| RGEN | REPLIGEN CORP. | $5,971,000 | -8.3% | 22,544 | 0.0% | 0.88% | -9.9% | |
| TARS | TARSUS PHARMACEUTICALS INC | $5,850,000 | +4.4% | 260,000 | 0.0% | 0.87% | +2.6% | |
| SPRB | SPRUCE BIOSCIENCES INC | $3,510,000 | -25.8% | 787,007 | 0.0% | 0.52% | -27.1% | |
| ABSCI CORP. | $474,000 | -29.5% | 57,804 | 0.0% | 0.07% | -30.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-01-21
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UIPATH INC | 9 | Q3 2023 | 30.2% |
| DOORDASH INC | 9 | Q3 2023 | 19.6% |
| SNOWFLAKE INC | 9 | Q3 2023 | 14.4% |
| ACUMEN PHARMACEUTICALS, INC | 9 | Q3 2023 | 10.0% |
| 908 DEVICES INC | 9 | Q3 2023 | 1.8% |
| TARSUS PHARMACEUTICALS INC | 9 | Q3 2023 | 1.4% |
| TAYSHA GENE THERAPIES INC | 9 | Q3 2023 | 2.0% |
| CANDEL THERAPEUTICS, INC | 9 | Q3 2023 | 1.3% |
| SPRUCE BIOSCIENCES INC | 9 | Q3 2023 | 0.7% |
| ABSCI CORPORATION | 9 | Q3 2023 | 0.1% |
View Sands Capital Ventures, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-15 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-09 |
View Sands Capital Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.